Switzerland-based NovImmune has begun dosing in a Phase I trial of a monoclonal antibody drug candidate NI-0101, with healthy volunteers.
The first-in-human study will evaluate the pharmacokinetic, pharmacodynamic, safety and tolerability profile of the drug candidate targeting toll-like receptor-4 (TLR4).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
NovImmune chief medical officer Cristina de Min said; "Data generated during this Phase I program, coupled with the information from pre-clinical experiments in relevant animal models for human diseases, will build a solid foundation to advance NI-0101 into Phase II studies."
In various preclinical models of arthritis, respiratory inflammation, organ injury and other autoimmune and inflammatory conditions, NI-0101 demonstrated efficacy of TLR4 blockade.
NI-0101 inhibits the ability of the subunits of the receptor complex to function together, thereby suppressing TLR4 signalling in spite of the pro-inflammatory signal.
TLR4 is a well characterised toll-like receptor with an important role as a key mediator of acute and chronic inflammation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTogether with other receptors, TLR4 generally plays a role in fighting invasions by responding to bacterial lipopolysaccharide as a pro-inflammatory stimulus.
When the body faces continuous inflammation, the cells get damaged and the products of damaged cells send pro-inflammatory signals by means of TLR4.
Such signals lead to self damage and inflammation which is the major reason behind several diseases. NI-0101 is designed to interrupt this activity, according to NovImmune.
